UC San Diego Sparks New Cancer-Focused Startup, Oncternal, with Exclusive Antibody License

Oncternal Therapeutics, a new cancer-focused biotechnology startup, has signed a wide-ranging licensing agreement with UC San Diego to develop and commercialize antibodies and antibody-related binding agents.

Oncternal is based on the pioneering research of UC San Diego scientist and clinician Thomas J. Kipps, Distinguished Professor, Evelyn and Edwin Tasch Chair in Cancer Research, and deputy director of research operations at the Moores Cancer Center on campus. … Read the Full Story from the UC San Diego Newsroom

UC San Diego Researcher Receives $6.25 Million Grant

The Leukemia & Lymphoma Society has awarded Thomas J. Kipps, MD, PhD, Distinguished Professor of Medicine at the University of California, San Diego School of Medicine, with a 5-year, $6.25 million Specialized Center of Research program grant to support research on chronic lymphocytic leukemia (CLL), the most common adult leukemia in the United States. … Read the full story from the UC San Diego News Center

Dr. Thomas Kipps

Dr. Thomas Kipps

Thomas J. Kipps, MD, PhD, is the Evelyn and Edwin Tasch Chair in Cancer Research and UC San Diego Moores Cancer Center deputy director for research.

See other UC San Diego news stories about Dr. Kipps and his work.